Journal of Bioequivalence & Bioavailability

Bioavailability: A pharmaceutical review

4^th World Congress on Bioavailability and Bioequivalence: Pharmaceutical R&D Summit

May 20-22, 2013 DoubleTree by Hilton, Beijing, China

Shaojing Hu

AcceptedAbstracts: J Bioequiv Availab

Abstract:

Recent years most of the candidate drugs that failed in clinical trials because of problems with ADME (absorption, distribution, metabolism, excretion) and toxicology, rather than through lack of efficacy. In sequence drug bioavailability becomes a hot topic of interest not only in drug development, but also in the early stages of drug discovery. By taking into account the ADME and toxicology aspects in drug discovery from very early stage, the pharmaceutical industry has improved with success rates to produce drug candidates with better bioavailability. Therefore, it is not surprising to see that the number of publications on drug bioavailability has been increasing steadily over these years. In this presentation will highlights the two main strategies to enhance the bioavailability of drugs, such as to improves drug solubility as well as drug permeability. Attention is also focused to briefly discuss some terms of bioavailability, relative bioavailability and bioequivalence, formulation and manufacturing variables that could influence the bioavailability of a drug product, physiologic and other factors affecting bioavailability, characteristics of drugs with the great potential for a bioavailability problem, assessment of bioavailability from pharmacologic as well as therapeutic response, bioavailability of drugs versus dietary supplements, causes of low bioavailability and different approaches to improve it based on biopharmaceutical classification system.

Biography :

Shaojin Hu, VP & Chief Chemist of Zhejiang Beta Pharma, Ph.D. in Organic Chemsitry from Simon Fraser University at Canada. Postrdoc from Yale University. Before join Zhejiang Beta Pharma, he severed as scientist, senior scientist, group leader and deputy chair of NPIC at two US pharmaceutical companies for over 13yrs. Dr. Hu is with extensive experience at drug R&D at metabolic diseases, oncology and CNS disease and related IP protection. He was elected as a member of the Chinese Program of Global Experts (also known as the ?1000 Plan?) in 2012. He has published more than 25 papers in reputed journals and more than 40 patents in his career.